Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 6/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1377085 | 0.93 | MAPK1 (0.51) | MAPK1HSD17B10NR1I2CYP2C9GAA | |
| SCHEMBL1376460 | 0.91 | MAPK1 (0.59) | MAPK1HSD17B10NR1I2CYP2C9GAA | |
| SCHEMBL1378291 | 0.91 | MAPK1 (0.50) | MAPK1HSD17B10NR1I2CYP2C9GAA | |
| SCHEMBL1522342 | 0.91 | MAPK1 (0.46) | MAPK1HSD17B10NR1I2CYP2C9MEN1 | |
| SCHEMBL1377769 | 0.90 | MAPK1 (0.49) | MAPK1HSD17B10NR1I2CYP2C9GAA | |
| SCHEMBL1377172 | 0.88 | HSD17B10 (0.48) | MAPK1HSD17B10NR1I2CYP2C9GAA | |
| SCHEMBL1379878 | 0.86 | HSD17B10 (0.47) | MAPK1HSD17B10NR1I2CYP2C9GAA | |
| SCHEMBL1378667 | 0.86 | MAPK1 (0.47) | MAPK1HSD17B10NR1I2CYP2C9MEN1 | |
| SCHEMBL1378475 | 0.85 | MAPK1 (0.48) | MAPK1HSD17B10NR1I2CYP2C9GAA | |
| SCHEMBL1522512 | 0.84 | MAPK1 (0.50) | MAPK1HSD17B10NR1I2CYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4738172-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| EP-1560827-A1 | ANTI-INFECTIVE AGENTS | Abbott Laboratories (US) | 2005-08-10 | — | — | EP | claimed |
| US-20050075331-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2005-04-07 | — | — | US | claimed |
| US-20040167123-A1 | Anti-infective agents | ABBVIE INC. | 2004-08-26 | — | — | US | claimed |
| US-20040162285-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-08-19 | — | — | US | claimed |
| WO-2004041818-A1 | ANTI-INFECTIVE AGENTS | ABBOTT LABORATORIES (US) | 2004-05-21 | — | — | WO | claimed |
| US-20040087577-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-05-06 | — | — | US | claimed |
| EP-2361913-A1 | Anti-infective agents | Abbott Laboratories (US) | 2011-08-31 | — | — | EP | disclosed |
| US-7902203-B2 | Anti-infective agents | ABBOTT LABORATORIES, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1560827-B1 | ANTI-INFECTIVE AGENTS | ABBOTT LAB (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1560827-A1 | ANTI-INFECTIVE AGENTS | Abbott Laboratories (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20050075331-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2005-04-07 | — | — | US | disclosed |
| US-20040167123-A1 | Anti-infective agents | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040162285-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-08-19 | — | — | US | disclosed |
| WO-2004041818-A1 | ANTI-INFECTIVE AGENTS | ABBOTT LABORATORIES (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040087577-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162285-A1 | Anti-infective agents | POLR1C, RPL5, POLB | MAPK1 1456/4885HSD17B10 1232/4885NR1I2 1899/4885 |
| US-20040167123-A1 | Anti-infective agents | SERPINB1, CYP51A1, ZC3HAV1 | MAPK1 739/4885HSD17B10 1422/4885NR1I2 1323/4885 |
| US-20050075331-A1 | Anti-infective agents | RPL35, POLI, POLRMT | MAPK1 2328/4885HSD17B10 1335/4885NR1I2 2436/4885 |
| US-20040087577-A1 | Anti-infective agents | POLR1C, RPL5, POLB | MAPK1 1456/4885HSD17B10 1232/4885NR1I2 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.